Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) Target Price at $23.83

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $23.8333.

ANRO has been the topic of several analyst reports. Chardan Capital upgraded Alto Neuroscience to a “strong-buy” rating in a report on Wednesday, November 19th. Robert W. Baird raised their price target on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. HC Wainwright raised their target price on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Finally, BTIG Research initiated coverage on shares of Alto Neuroscience in a research report on Monday, November 17th. They issued a “buy” rating and a $27.00 price objective for the company.

Institutional Trading of Alto Neuroscience

Hedge funds have recently bought and sold shares of the stock. SCS Capital Management LLC bought a new position in Alto Neuroscience in the first quarter valued at $144,000. Nuveen LLC bought a new position in shares of Alto Neuroscience during the 1st quarter worth approximately $302,000. Peapod Lane Capital LLC bought a new position in shares of Alto Neuroscience in the second quarter valued at about $613,000. AWM Investment Company Inc. lifted its position in Alto Neuroscience by 31.1% during the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after acquiring an additional 214,153 shares during the last quarter. Finally, AlphaCore Capital LLC lifted its holdings in Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the last quarter.

Alto Neuroscience Stock Up 1.1%

ANRO opened at $19.88 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The company has a market capitalization of $617.67 million, a PE ratio of -8.68 and a beta of 2.95. The business has a 50-day moving average of $13.96 and a 200-day moving average of $7.11. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $20.91.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Equities research analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.